Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

Deborah Grayson, who goes by the moniker 'The Godmother of Pharmacology', said there had been a rise in patients taking the ...